chevron_leftBack
As of 13 June 2026, LeonaBio, Inc. has a market cap of $26.62M USD, ranking #35074 globally and #4852 in the United States.
It ranks #3165 in the Healthcare sector, and #609 in the Biotechnology industry.
Key Stats
Market Cap
$26.62MUSD
Enterprise Value
-$6.74MUSD
EBITDA (TTM)
-$33.21MUSD
Net Income (TTM)
-$105.61MUSD
PB Ratio
2.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mark Litton
open_in_new
Employees
19
Founded
2011
IPO
18 Sep 2020
Website
leonabio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.9% | -6.6% | -4% | 78% | 104% | 193% |
News
Loading...
ATHA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ATHA
Athira Pharma Inc Ordinary Shares
ISIN: US04746L2034
Shares Out.:
Shares Outstanding:
3.944M1
Shares Float:
3.245M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
8.77 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
685K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
601K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
104K%
|
-
|
|
NYSE: IQV
|
$26.3B
99K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
94K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
68K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
180K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
168K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
159K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
159K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
106K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
96K%
|
-
|
chevron_leftBack